Cytek Biosciences, Inc.
CTKB
$4.28
-$0.09-1.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.52% | -2.18% | -0.85% | -1.86% | 3.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.52% | -2.18% | -0.85% | -1.86% | 3.85% |
| Cost of Revenue | 8.60% | 0.98% | 0.36% | -0.65% | 6.89% |
| Gross Profit | -5.98% | -4.77% | -1.83% | -2.83% | 1.54% |
| SG&A Expenses | 17.51% | 6.63% | 2.95% | -0.17% | -0.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.46% | 1.68% | -0.28% | -2.37% | 0.05% |
| Operating Income | -96.78% | -34.50% | -4.04% | 6.26% | 26.30% |
| Income Before Tax | -423.62% | -30.02% | 53.48% | 49.10% | 63.72% |
| Income Tax Expenses | 11,368.13% | -52.23% | -189.03% | 179.00% | 108.99% |
| Earnings from Continuing Operations | -1,005.48% | -26.19% | 63.54% | 2.24% | 50.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,005.48% | -26.19% | 63.54% | 2.24% | 50.45% |
| EBIT | -96.78% | -34.50% | -4.04% | 6.26% | 26.30% |
| EBITDA | -146.46% | -45.69% | -2.53% | 11.67% | 38.93% |
| EPS Basic | -1,065.02% | -29.32% | 61.64% | -0.82% | 49.72% |
| Normalized Basic EPS | -453.41% | -33.57% | 51.23% | 47.54% | 63.33% |
| EPS Diluted | -911.26% | -29.25% | 60.04% | -0.33% | 43.65% |
| Normalized Diluted EPS | -453.41% | -33.57% | 51.23% | 47.54% | 63.33% |
| Average Basic Shares Outstanding | -2.19% | -2.85% | -3.14% | -3.11% | -3.45% |
| Average Diluted Shares Outstanding | -2.53% | -3.18% | -2.81% | -2.78% | -3.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |